The transcription factor nuclear factor kB (NFkB) is a central regulator of inflammation, and genome-wide association studies in subjects with autoimmune disease have identified a number of variants within the NFkB signaling cascade. In addition, causal variant fine-mapping has demonstrated that autoimmune disease susceptibility variants for multiple sclerosis (MS) and ulcerative colitis are strongly enriched within binding sites for NFkB. We report that MS-associated variants proximal to NFkB1 and in an intron of TNFRSF1A (TNFR1) are associated with increased NFkB signaling after tumor necrosis factor-a (TNFa) stimulation. Both variants result in increased degradation of inhibitor of NFkB a (IkBa), a negative regulator of NFkB, and nuclear translocation of p65 NFkB. The variant proximal to NFkB1 controls signaling responses by altering the expression of NFkB itself, with the GG risk genotype expressing 20-fold more p50 NFkB and diminished expression of the negative regulators of the NFkB pathway: TNFa-induced protein 3 (TNFAIP3), B cell leukemia 3 (BCL3), and cellular inhibitor of apoptosis 1 (CIAP1). Finally, naïve CD4 T cells from patients with MS express enhanced activation of p65 NFkB. These results demonstrate that genetic variants associated with risk of developing MS alter NFkB signaling pathways, resulting in enhanced NFkB activation and greater responsiveness to inflammatory stimuli. As such, this suggests that rapid genetic screening for variants associated with NFkB signaling may identify individuals amenable to NFkB or cytokine blockade.
INTRODUCTION
Nuclear factor kB (NFkB) was one of the first transcription factors identified and is a central regulator of inflammation (1) . The canonical p50/p65 NFkB signaling cascade is critical for activation of immune responses downstream of T and B cell receptors, toll-like receptors, and cytokines, including tumor necrosis factor-a (TNFa) and interleukin1b (IL-1b). Moreover, alterations in NFkB have been associated with both autoimmune disease and malignancies (2, 3) . Inflammatory autoimmune diseases, which reflect complex interactions between genetic variation and environment, are important systems for genetic investigation of human disease. These diseases share a substantial degree of immunopathology, with increased activity of autoreactive CD4 + T cells secreting inflammatory cytokines and loss of regulatory T cell function (4) (5) (6) (7) . Multiple sclerosis (MS) is one such autoimmune disease where there is chronic inflammation in the central nervous system (CNS), with infiltration of activated mononuclear cells into the CNS that damages both myelin and axons. This complex genetic disease is associated with environmental factors that appear to drive a predominantly T cell autoimmune response against CNS antigens (8, 9) .
Genome-wide association studies (GWAS) and subsequent targeted genomic studies have identified 97 variants associated with MS susceptibility (10) (11) (12) . Although each of these variants contributes only a small increase in the complex phenotype of disease risk, the biological function associated with individual allelic variants has been striking (13) (14) (15) (16) (17) . Many of these variants fall within specific signaling cascades, suggesting that alterations in pathways, rather than individual genes, may be the key to understanding how individual variants with small odds ratios result in disease susceptibility (18) (19) (20) . About 17% (17 of 97) of MS susceptibility variants identified by GWAS fall either within or proximal to NFkB signaling genes, including variants proximal to NFkB1 itself and within TNF receptor 1 (TNFR1) (10, 12, 21) .
We recently integrated genetic and epigenetic fine-mapping to identify potentially causal variants in autoimmune disease-associated loci and explore their functions by generating cis-regulatory element maps for a spectrum of immune cell types. About 60% of likely causal variants map to enhancer-like elements, with preferential enrichment in stimulus-dependent CD4 + T cell enhancers. When overlapping causal single-nucleotide polymorphisms (SNPs) with 31 transcription factor binding maps generated by ENCODE, SNPs were strongly enriched within binding sites for immune-related transcription factors, and variants associated with different diseases correlate to different combinations of transcription factors that control immune cell identity and response to stimulation. In patients with MS, SNPs preferentially coincide with NFkB-, EBF1 (early B cell factor 1)-, and MEF2A (myocyte enhancer factor 2A)-bound regions (22) .
Previous studies have shown that total peripheral blood mononuclear cells (PBMCs) from relapsing-remitting MS (RRMS) patients exhibit increased levels of active NFkB (23) . We similarly observed that naïve CD4 T cells from RRMS patients exhibit increased activation of the canonical p65 NFkB pathway compared to healthy controls, suggesting that this difference is not due to the activation status of the cells. Thus, we hypothesized that the alterations in NFkB signaling seen in patients with MS are a result of SNPs in the NFkB signaling cascade associated with MS susceptibility. Because NFkB signaling is triggered by many environmental stimuli through toll-like receptors, this may represent a critical intersection between genetic and environmental factors resulting in MS development. However, the impact of autoimmunity-associated genetic variants on the biological function of this major transcription factor is unknown.
It has been shown that mice with a constitutively active form of p65 NFkB exhibit multiorgan inflammation and die within 3 weeks of birth. However, when these mice with constitutively active p65 NFkB were bred back to mice lacking TNFR1, they were protected from inflammation and exhibited only a mild Sjogren's syndrome-like ocular keratitis, indicating a critical role of the NFkB/TNF pathway in regulating autoimmune disease (24) . Variants within or proximal to both TNFRSF1A (TNFR1) and NFkB1 have been identified by GWAS as being associated with risk of developing MS. Therefore, we chose to focus our studies on these SNPs to determine whether they alter NFkB responses.
Here, we investigated the effect of MS risk haplotypes on the function of the NFkB signaling cascade. We demonstrate that both the haplotype with the variant proximal to NFkB1 (rs228614-G) and that with the variant within TNFR1 (rs1800693-C) result in enhanced NFkB responses to TNFa. The rs228614-G risk allele also enhances responses to phorbol 12-myristate 13-acetate (PMA), suggesting that this variant strongly controls NFkB signaling. Mechanistically, we found that rs228614-G is associated with a 20-fold increase in p50 NFkB expression and decreased expression of the negative regulators of NFkB signaling. These findings elucidate a genetic mechanism controlling NFkB responses that result in predisposition to developing MS.
RESULTS

Patients with MS have increased activation of the canonical NFkB cascade
Previous reports suggest that total PBMCs from patients with MS exhibit increased activity of NFkB, consistent with excessive immune activation (23, 25) . However, it was not possible to determine whether this increased NFkB activation is due to up-regulation of NFkB or to the increased frequency of activated and memory CD4 T cells in patients with MS. To resolve this question, we isolated total PBMCs from patients with MS and healthy control subjects ex vivo and directly stained for phospho-p65 NFkB. We found that naïve CD4 cells from patients with MS exhibit significantly higher phospho-p65 NFkB than those from age-matched healthy control donors, and this increased activation of p65 NFkB was mitigated by treatment ( Fig. 1 ; subject demographics are listed in table S1). This increased constitutive expression of phospho-p65 NFkB was repeated in a second cohort of MS patients and healthy controls ( fig. S1 ). The presence of enhanced activation of NFkB in naïve CD4 cells demonstrates that this is not due to an increase in the number of activated or memory cells but is rather due to a hyperactivated state of CD4 cells.
The MS risk variant rs228614 near NFkB1 is associated with increased NFkB signaling To determine whether the increased NFkB activation seen in patients with MS may be due to genetic variation in the NFkB signaling cascade associated with disease susceptibility, we next assessed whether the MS risk variant proximal to NFkB1 increases NFkB signaling. The SNP rs228614 on chromosome 4 is associated with MS susceptibility (odds ratio of 1.09 per G allele carried; P = 1 × 10
) and lies near the NFkB1 gene (12) . It is part of a haplotype of more than 90 variants in tight linkage disequilibrium (LD) that spans the region encoding both NFkB1 and MANBA ( Fig. 2A) . Although this strong LD precludes identifying this specific SNP as the causal variant for disease, we stratified donors into those carrying one or two copies of the G risk allele (rs228614-G) and correlated NFkB signaling to genotype in total PBMCs. In addition, we also investigated a second variant, rs7665090, in LD to rs228614 (r 2 > 0.8) that was identified by fine-mapping as the most associated variant in the region (10) . This allowed us to examine two variants within the same region to determine the impact on NFkB signaling and thus address the difficulty of identifying the causal variant in genetic mapping studies. We used healthy control subjects carrying the risk or protective variants to avoid the confounding factors of ongoing inflammation and therapeutic intervention seen in patients with MS.
We collected blood samples from healthy donors in our previously genotyped biorepository of recallable subjects (Yale Phenogenetic Project) (see demographics in tables S2 and S3). We found that the MS risk alleles rs228614-G and rs7665090-G are significantly associated with an increase in inhibitor of NFkB a (IkBa) degradation after TNFa stimulation (allelic logistic regression: rs228614, P = 0.00078, and rs7665090, P = 0.01; Fig. 2B ). This difference is also significant when comparing homozygous risk and protective genotypes (Student's t test between GG and AA carriers: rs228614, P = 0.0091; rs7665090, P = 0.0089; Fig. 2B ). Risk allele homozygotes showed consistently increased phosphorylation of p65 NFkB (Student's t test between GG and AA carriers: rs228614, P = 0.029; rs7665090, P = 0.039; Fig. 2C , representative histogram and gating strategy in fig. S2 ). A trend of increased signaling from both rs228614 and rs7665090 was also observed at 15, 30, and 45 min ( fig. S3) . Thus, the region containing the rs228614 and rs7665090 SNPs modulates TNFa signaling through NFkB.
To determine whether this represents a global impact on NFkB signaling or a specific alteration in TNFa signaling, we stimulated total PBMCs from subjects with the different genotypes at rs228614 with PMA, an activator of NFkB independent of TNFa. The risk genotype (GG) resulted in greater degradation of IkBa and phosphorylation of p65 NFkB in naïve CD4 cells after stimulation with PMA, suggesting a modulation of global NFkB responses rather than to a specific stimulus ( Fig. 2D ; IkBa, P = 0.019 and pNFkB, P = 0.027). To determine whether this region was also affecting NFkB signaling in MS patients, we stimulated total PBMCs from rs7665090 homozygous risk (GG) and protective (AA) subjects with TNFa and determined degradation of IkBa and phosphorylation − T cells. Healthy control, n = 34; untreated MS, n = 11; treated MS, n = 25. P value shown for unpaired t test. n.s., not significant. of p65 NFkB by flow cytometry. Similar to the changes in NFkB signaling seen in healthy controls, the risk variant also resulted in increased IkBa degradation ( Fig.  2E ) and phosphorylation of p65 NFkB (Fig. 2F ) in naïve CD4 cells in MS patients. We hypothesized that these divergent NFkB responses should result in differential rates of nuclear localization of p65 NFkB. We tested this by comparing healthy donors with AA (protective) and GG (risk) genotype at rs228614. We stimulated CD4 cells with TNFa for 15 or 30 min, stained for p65 NFkB and 4′,6-diamidino-2-phenylindole (DAPI), and determined nuclear localization of p65. We found that GG carriers demonstrate increased p65 nuclear localization after 30 min, confirming stronger signaling responses ( Fig. 3 , A and B). Together, these data demonstrate that the MS risk haplotype captured by rs228614 and rs7665090 strongly modulates NFkB responses, with the GG risk genotype resulting in enhanced NFkB signaling.
rs228614 is associated with changes in the expression of NFkB1 and the negative regulators of the NFkB pathway We did not find differences in IkBa and phospho-p65 NFkB expression in resting CD4 cells, suggesting that the effect of the rs228614 risk variant is only evident after signaling induction ( fig. S4 ). This suggests that the underlying causal variant perturbs regulatory elements controlling stimulus-dependent activation of the NFkB gene, consistent with the observation that most GWAS risk variants alter gene regulation rather than structure (26) . The haplotype block containing rs228614 spans the coding regions of NFkB1 and MANBA and the intergenic space between them, which contains at least 62 transcription factor binding sites, 12 regions of DNA hypersensitivity, 3 insulator regions, and multiple putative enhancer regions active in both T cell and myeloid cell lineages (27) (28) (29) (30) (31) (32) (33) , suggestive of important regulatory functions. We therefore looked for changes in expression of p50 NFkB in rs228614 GG and AA genotype carriers by Western blot.
We found that subjects with the GG risk genotype express p50 NFkB at a 20-fold higher level than the AA genotype ( Fig. 4A  and fig. S5 , uncut blot). We also found a + CD45RO − T cells after TNFa stimulation by flow cytometry in MS patients. For (A) to (D): rs228614 GG, n = 4; AG, n = 18; AA, n = 6; rs7665090 AA, n = 8; AG, n = 49; GG, n = 23. For (E) and (F), GG, n = 6; AA, n = 6. P value shown for homozygous unpaired t test.
commensurate decrease in mRNA levels in total PBMCs of three key negative regulators of NFkB [TNFa-induced protein 3 (TNFAIP3), B cell leukemia 3 (BCL3), and cellular inhibitor of apoptosis 1 (CIAP1)] in the GG homozygotes (Fig. 4B) . Together, these results suggest that an increase in total p50 NFkB and a loss of negative regulation of this pathway are responsible for enhanced signaling. Although IkBa degradation is upstream of NFkB, signaling through NFkB regulates the expression of NFkB1 itself, as well as the negative regulators of NFkB. Thus, we demonstrate alterations in the expression of both NFkB1 and the negative regulators of this pathway, suggesting that the MS risk allele causes a fundamental shift in the regulation of NFkB signaling.
NFkB responses are stable over time and are not associated with age or gender If the strength of NFkB signaling is primarily mediated by genetic variability between individuals and not by changes in environmental or external stimuli, we would expect consistent strength of signal across multiple time points. We redrew 15 subjects on an average of 6 months after the first blood draw. We found no statistically significant difference between draws (fig. S6). Although there was significant variability between individuals in the strength of NFkB signaling, the stability in this variability across multiple draws was consistent with a genetically mediated threshold for NFkB signaling.
It has been shown that individuals 65 years or older have an increase in constitutive activation of p65 NFkB (34) . The Phenogenetic Project enrolled subjects up to age 56 years at the time of enrollment, and subjects were consented for redraws for up to 4 years. To determine whether NFkB signaling changes with age, we compared age at blood draw to NFkB signaling after TNFa stimulation. We found no correlation between age and strength of signal by either IkBa degradation or phosphorylation of p65 before the age of 60 years ( fig. S7, A and B) . This suggests that changes in NFkB signaling associated with aging only occur after 60 years of age. We also found no differences in gender or ethnicity in NFkB signaling after TNFa stimulation ( fig. S7, C to F) . rs1800693 in TNFR1 is associated with enhanced NFkB responses to TNFa Because both NFkB and TNFR1 are important in autoimmune inflammation and variants near both NFkB1 (rs266814) and TNFRSF1A (rs1800693) are associated with risk of developing MS (12), we investigated the impact of the TNFRSF1A variant on NFkB signaling. Unlike the NFkB1 locus, where tight LD precludes identifying the likely causal SNP, rs1800693 alone best explains the association signal in the TNFRSF1A region and is thus likely causal (10) . The variant falls 10 base pairs upstream of TNFRSF1A exon 6 in a splice acceptor site (Fig. 5A ). We and others have previously shown that homozygous carriers of the rs1800693-C risk allele show loss of exon 6 and a premature stop codon in~10% of TNFR1 mRNAs (35, 36) . Moreover, this variant results in an exaggerated cytokine production response from monocytes after stimulation with TNFa (35) 5B ) and monocytes (P = 0.011; Fig. 5C ) compared to TT genotype carriers. Unlike the variant proximal to NFkB1, there were no differences in signaling after PMA stimulation between the CC and TT genotypes (Fig. 5B) . These data suggest that rs1800693 is associated with changes in signaling only when TNFa binds to TNFR1. TNFa can signal through two receptors, TNFR1 and TNFR2. Naïve CD4 cells primarily express TNFR1, with TNFR2 being up-regulated after activation (37). Our results suggest that altered TNFainduced signaling is due to rs1800693-C exerting regulatory effects on TNFR1. To validate this model, we blocked TNFR1 and found that TNFa signaling in naïve CD4 cells occurs exclusively through TNFR1, with no contribution from TNFR2 ( fig. S8 ). As such, the changes in signaling observed in naïve CD4 cells can be attributed directly to alterations in TNFR1. To confirm these changes in NFkB signaling in CD4 cells, we purified total CD4 cells, stimulated them with TNFa for 15 or 30 min, and determined the amount of p65 NFkB nuclear localization. We observed an increase in nuclear localization 15 min after stimulation in carriers of the CC genotype compared to the TT genotype (Fig. 6, A and  B) . The CC genotype did not result in changes in the cell surface expression of TNFR1 on naïve CD4 cells, either as a percentage of cells expressing TNFR1 or the expression level of TNFR1 on the surface ( fig.  S9 ). This suggests that the change in signaling is not due to changes in overall TNFR1 levels on the cell surface. We and others have shown that expression of the prematurely terminated transcript missing exon 6 caused by the rs1800693-C allele results in altered intracellular accumulation of TNFR1 in human embryonic kidney (HEK) 293 cells or HeLa cells (35, 36) . We investigated whether this is true in primary immune cells directly ex vivo and found that CD14 + monocytes from CC risk genotype carriers exhibit altered intracellular accumulation of TNFR1 into punctate structures within the cytoplasm (Fig. 7A, singlestained control, fig. S10 ). Together, these results demonstrate that the variant in TNFR1 results in increased signaling to TNFa in both naïve CD4 cells and monocytes and that this altered signaling may be due to altered localization of TNFR1 within the cell. rs1800693 in TNFR1 is associated with increased plasma cytokines in healthy controls consistent with levels seen in MS patients Because TNFa signaling drives the expression of inflammatory cytokines, we examined whether changes in TNFR1-mediated signaling associated with the rs1800693-C risk allele result in altered plasma cytokines levels. We measured plasma levels for 29 cytokines in healthy subjects and found that CC genotype carriers have increased plasma levels of IL-7, IL-8, granulocyte-macrophage colonystimulating factor (GM-CSF), interferon-inducible protein 10 (IP10), and monocyte chemoattractant protein 1 (MCP1) (Fig. 7B and table S5 ). This is consistent with our previous findings that IP10 is overexpressed in monocytes after TNFa stimulation in CC genotype carriers (35) . It has been reported that IL-7, GM-CSF, IP10, IL-8, and MCP1 are increased in serum of patients with MS (38) (39) (40) (41) (42) . In addition, recent twin studies have shown that serum concentrations of all five of these cytokines are highly heritable (43) . This demonstrates that the CC homozygous risk genotype alters inflammation levels in healthy control subjects, consistent with that seen in MS.
DISCUSSION
NFkB is a central regulator of inflammation, controlling the activation, proliferation, and cytokine production of immune responses. We observed that naïve CD4 T cells from patients with the autoimmune disease MS exhibit increased activation of p65 NFkB, prompting us to investigate the genetic control of NFkB signaling in the disease. We found that variants near genes in the NFkB signaling cascade have large effects on NFkB signaling. Specifically, the allelic variant proximal to NFkB1 controls signaling responses by altering the expression of NFkB itself, with the GG risk genotype expressing 20-fold more p50 NFkB. This genotype is associated with altered NFkB responses to both TNFa and PMA, suggesting a global control of NFkB signaling. Because causal SNPs are strongly enriched within binding sites and signaling molecules for NFkB, these results demonstrate a central role for NFkB in driving the pathophysiology of MS.
The region spanned by the MS risk haplotype near NFkB1 contains a large number of gene regulatory elements, as mapped by the ENCODE project (27) (28) (29) (30) (31) (32) (33) . This suggested the hypothesis that the MS risk allele affects NFkB1 expression and thus alters NFkB signaling. To investigate this potential mechanism, we examined how allelic variation in this region influenced expression of p50 NFkB and found that MS risk variants are strongly associated with large increases in expression. Consistent with increased NFkB signaling, there was a decrease in expression of the negative regulators of NFkB, suggesting a global disruption in the NFkB cascade. The central role of NFkB in immune activation would suggest that this MS haplotype broadly increases inflammatory responses, thereby predisposing individuals to autoimmunity.
We recently investigated the overlap of potentially causative SNPs with 31 transcription factor binding maps generated by ENCODE and observed that they were strongly enriched within binding sites for immune-related transcription factors (22) . Moreover, variants associated with different autoimmune diseases correlate with different combinations of transcription factors that control immune cell identity and response to stimulation. We found that MS SNPs preferentially coincide with NFkB-, EBF1-, and MEF2A-bound regions, whereas rheumatoid arthritis and celiac disease SNPs preferentially coincide with IRF4 (interferon regulatory factor 4) regions (22) . Thus, both GWAS and epigenetic mapping strongly implicate NFkB as a critical pathway , and CIAP1 in total PBMCs (GG, n = 6; AA, n = 7). P value shown for unpaired t test. associated with MS. That is, variants associated with MS tend to fall in or near genes involved in NFkB signaling, and secondly, variants associated with MS frequently fall near known NFkB response elements. We propose a model in which variants associated with NFkB signaling and binding interact to form a cumulative burden on this critical pathway. The enhanced NFkB activity we observe in naïve CD4 cells suggests that these cells may have a decreased threshold of activation, thereby making them more susceptible to low levels of stimuli and ultimately autoimmunity.
We also established that an MS risk variant intronic to TNFRSF1A (TNFR1) is associated with increased NFkB signaling in response to TNFa. We confirmed previous reports that this risk variant results in an altered intracellular accumulation of TNFR1 and extended these findings to show that monocytes isolated from peripheral blood show this altered phenotype (35, 36) . Notably, an R92Q mutation in TNFR1 is associated with TNFR-associated periodic syndrome (TRAPS), a relapsing-remitting peripheral inflammatory disorder. The R92Q mutation also results in an altered intracellular accumulation of TNFR1 and increased responses to inflammatory stimuli (44) . This may suggest a common mechanism for altered NFkB-mediated signaling between MS and TRAPS.
We have previously reported that CD4 cells from MS patients exhibit increased proliferation at low doses of anti-CD3 stimulation compared to healthy controls (45) . These data suggest a decreased threshold for activation of CD4 cells in patients with MS, consistent with genetic risk variants perturbing NFkB pathway genes to create a net increase in signaling through this inflammatory cascade.
Treatments that suppress NFkB signaling, such as steroids, are routinely used in MS, although their prolonged use is ineffective, perhaps because of the many mechanisms associated with chronic steroid usage. Although these studies might support the use of NFkB inhibitors in MS, they also suggest that it may be possible to determine the specific stimuli and downstream signaling cascades that may identify novel disease treatments. Notably, TNFa blockade by monoclonal antibodies or soluble receptors is highly effective in many autoimmune diseases. In contrast, TNFa blockade in patients with MS worsens disease and induces new-onset MS in some patients with rheumatoid arthritis, Crohn's disease, and ulcerative colitis (46) . Moreover, TNFa blockade can also initiate psoriasis and induce the development of anti-nuclear or double-stranded DNA antibodies in up to 70% of other autoimmune patients, with some progressing to anti-Rho/La antibodies and clinical lupus (46, 47) . Blocking TNFa in patients with mutations in TNFR1 associated with TRAPS also results in increased NFkB signaling and inflammation similar to that seen in MS (48) . These data emphasize the clinical importance of understanding the NFkB pathway in MS and other autoimmune diseases and implicate genetic variants in the TNF signaling pathway as controlling the altered responses to anti-TNFa therapy. The haplotype block surrounding the intergenic region downstream of NFkB1 contains more than 90 variants in strong LD, and we were unable to identify a single most likely causal variant by genetic and epigenetic fine-mapping. In the future, the use of probabilistic identification of causative SNPs in larger cohorts may allow further fine-mapping of this region, which may better identify the most likely causative SNP (22) . In spite of this lack of resolution in the discovery process, we are able to show that the underlying MS variant in this region tagged by the rs228614-G allele is strongly associated with NFkB responses to TNFa.
We demonstrated that significant interindividual variation exists in NFkB responses, and this variability is partially mediated by genetic variability in the NFkB signaling cascade. Because many autoimmune diseases and cancers have genetic variants associated with NFkB, it is likely that genetically mediated variability in this pathway is central to disease risk. In addition, because the variants associated with each disorder are different, variation in the NFkB pathway may result in changes in signaling that are specific to each disease. Finally, the increased NFkB signaling we observed is consistent with the enhanced activation of the canonical NFkB pathway observed in naïve CD4 cells from patients with MS. Hyperactivation of NFkB in mice results in rapid postnatal death from massive multiorgan inflammation not seen in human disease (24, 49). As such, it is likely that dysregulation of Y axis shows the GWAS -log(P value) for the allelic test of association as reported in (10) . We have highlighted rs1800693, the most associated variant in the region. With further replication data in independent samples, rs228614 meets the GWAS significance threshold of P < 5 × 10 NFkB represents a necessary factor in the development of autoimmunity but that other factors are also required to determine the location and nature of the inflammatory insult. Current GWAS have identified variants associated with disease susceptibility but do not determine how these variants are affecting disease severity or progression. Given that NFkB signaling is critical for both inflammation and neuronal degeneration (50) , this pathway may represent a node that both predisposes to disease and contributes to disease progression.
In conclusion, naïve CD4 T cells from patients with MS exhibit increased p65 activation, consistent with changes in NFkB signaling. We observe equivalent changes in healthy controls carrying MS risk variants, which alter NFkB responses to TNFa, suggesting that disease risk is mediated by gene regulatory changes resulting in altered NFkB signaling. Because SNPs causal for MS are enriched in binding sites and signaling molecules for NFkB, these data demonstrate a central role for NFkB in driving the pathophysiology of MS. Identifying these critical nodes may suggest novel therapeutics aimed at specifically targeting the underlying causes of disease while leaving systemic immune responses primarily intact.
MATERIALS AND METHODS
Study design
Healthy subjects between the ages of 18 and 56 years at the time of initial assessment were enrolled in the Yale Phenogenetic Project and could be recalled up to six times a year for up to 4 years. Subjects with autoimmune disorders were excluded from the repository. In addition, any subjects exhibiting illness or fever at the time of draw were excluded. Investigation of the impact of rs228614 and rs7665090 on phospho-p65 NFkB and total IkBa was performed blinded, with the strength of signal determined before genotyping the samples. Samples were unblinded, and comparison of strength of signal to genotype was performed after unblinding. For blinded studies, power calculations determined that a singleton quantitative trait locus with a variance of 10% and an allele frequency of 20% could generate a significance of 0.05 for overall association with 50 samples and 0.01 with 90 samples. Because rs228614, rs7665090, and rs1800693 all have minor allele frequencies of >30%, these studies were sufficiently powered to generate significance. Nuclear localization, Western blotting, and qPCR studies were performed on recalled samples with specific genotypes. All TNFRSF1A studies were performed on samples of risk and protective genotypes recalled from the Brigham and Women's Hospital (BWH) PhenoGenetic Project. All studies were performed to at least three biological replicates. + T cells (CC, n = 9; TT, n = 9). Nuclear localization is shown normalized to unstimulated cells. P value shown for unpaired t test. 
Blood repositories
Samples were acquired from the Yale Phenogenetic Project or the BWH PhenoGenetic Project. These samples have been genotyped for autoimmunity-associated SNPs by Illumina Chip. Blood was drawn into heparin tubes. Samples from Yale were prepared immediately after blood draw. TNFR1 samples from BWH were shipped overnight with room temperature gel packs (SAF-T-PAK) and prepared the following morning. RRMS from age-and gender-matched blood was drawn at the Yale MS Clinic and prepared the same as the healthy control samples. All samples were compared to samples from the same source (Yale or BHW).
PBMC preparation and cell purification PBMCs were prepared from whole blood by Ficoll-Hypaque density gradient centrifugation. For some experiments, total CD4 cells or CD14 + monocytes (containing both CD16 + and CD16 − ) were purified by magnetic negative selection using EasySep magnetic separation kits (Stem Cell Technologies).
Cytokine stimulation
Total PBMCs were rested for 1 hour in RPMI medium without fetal bovine serum (FBS) after isolation. Monocytes were plated overnight in RPMI medium containing 5% FBS, L-glutamine, nonessential amino acids, sodium pyruvate, and Hepes. Monocytes were washed two times with RPMI and rested for 1 hour with RPMI without FBS before stimulation. Stimulation was performed with TNFa (50 ng/ml; R&D Systems) or PMA (500 ng/ml; Sigma-Aldrich). Cells were fixed at 15, 30, or 45 min with BD fixation buffer (BD Biosciences), washed two times with phosphate-buffered saline (PBS), and permeabilized with ice-cold BD permeabilization buffer III (BD Biosciences). Cells were permeabilized overnight at −80°C. After being washed, the cells were stained for CD4 phycoerythrin (PE), CD45RA AF700, CD45RO PE-Cy7, phospho-p65 NFkB (pS529) (BD Biosciences), and IkBa A488 (Cell Signaling Technologies). Flow cytometry was performed on a BD LSRII Fortessa (BD Biosciences). Analysis was performed using FlowJo software (TreeStar).
Nuclear localization
Total CD4 cells were stimulated with TNFa (50 ng/ml; R&D Systems) for 15 or 30 min. Cells were fixed with 3% formalin for 10 min, washed, and permeabilized with 0.1% Triton X-100 + 2% FBS in PBS (no Ca/Mg). Cells were blocked with Fc Block (eBioscience). p65 NFkB was stained with anti-p65 NFkB (Santa Cruz Biotechnology) and fluorescein isothiocyanate (FITC)-labeled donkey Fab2 anti-rabbit immunoglobulin G (IgG) (Jackson ImmunoResearch). Cells were stained with DAPI (Sigma-Aldrich) nuclear stain for 10 min and washed twice with PBS. Nuclear localization was performed on an Amnis Imagestream x or Amnis Imagestream
x Mark II at ×40 or ×60 magnification. Nuclear localization was determined using Amnis IDEAS software (Amnis) by Pearson coefficient colocalization of DAPI and p65 NFkB.
Western blot
Total PBMCs were lysed with radioimmunoprecipitation assay buffer (Pierce) containing Halt protease inhibitors (Pierce). Total protein was determined by bicinchoninic acid assay (Pierce), and 10 mg of total protein was run per lane. Samples were prepared with loading buffer (Life Technologies) and heated for 10 min at 72°C before running on Western blot. Samples were run on a 10% bis-tris gel and transferred onto nitrocellulose with the XCELL Western blot transfer apparatus (Life Technologies). Blots were blocked with 1× tris-buffered saline (TBS) and 0.1% Tween 20 with 5% (w/v) nonfat dry milk overnight. p105/p50 NFkB and actin (Cell Signaling Technology) were stained overnight, washed three times with 1× TBS and 0.1% Tween 20, and labeled with horseradish peroxidase-linked anti-mouse IgG (Cell Signaling Technologies). Blots were developed using ECL Prime (GE Healthcare). Densitometry was performed using ImageJ analysis software [National Institutes of Health (NIH)].
Confocal microscopy
Two hundred thousand monocytes were plated overnight in 24-well plates with poly-L-lysine-coated coverslips. Cells were incubated overnight, fixed with 3% formalin, and permeabilized with 0.1% Triton X-100 + 2% FBS in PBS (no Ca/Mg). Cells were blocked with Fc Block (eBioscience) and a cocktail of 1% FBS, 1% donkey serum, and 1% human serum. TNFR1 was stained with polyclonal TNFR1 antibody (R&D Systems) and labeled with FITC-labeled anti-rabbit IgG (Jackson ImmunoResearch). Images were captured on a Leica microscope (Leica Biosystems) and analyzed using ImageJ software (NIH).
Luminex
Plasma was prepared by centrifuging total blood at 5000 rpm for 10 min and removing the plasma fraction from the red cell fraction. Plasma was immediately frozen at −80°C until run on a 30-plex Luminex (Millipore).
Quantitative PCR RNA was extracted from whole PBMCs using Qiagen RNeasy Plus Micro Kit according to the manufacturer's instructions. Sample concentration and purity were determined by spectrophotometer analysis on NanoDrop 2000. Complementary DNA was prepared from RNA through reverse transcription-PCR with reverse transcriptase kits from Life Technologies. qPCR was performed using primers for TNFAIP3 (hs00234713_m1), BCL3 (hs00180403_m1), CIAP1 (BIRC2, Hs01112284_m1), and the housekeeping genes HPRT (hs01003267_m1) and b2M (H500984230_m1) with TaqMan Fast Universal PCR Master Mix (No AmpErase Uracil N-Glycosylase) (Life Technologies). Samples were run on an ABI Prism quantitative PCR machine (Life Technologies).
Statistics
Genotype-phenotype associations were calculated in two ways: an allelic test as implemented in PLINK (51) and comparing opposite homozygote groups by unpaired t test, as implemented in PRISM (GraphPad). In both cases, uncorrected P values were reported.
Study approval
The study was conducted in compliance with the Declaration of Helsinki. Before study initiation, approval was obtained from the ethics committee of Yale-New Haven Hospital. Informed consent was received from all subjects before inclusion in the study.
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